Your browser doesn't support javascript.
loading
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
Baraliakos, Xenofon; Kivitz, Alan J; Deodhar, Atul A; Braun, Jürgen; Wei, James C; Delicha, Eumorphia Maria; Talloczy, Zsolt; Porter, Brian.
Afiliação
  • Baraliakos X; Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Germany. xenofon.baraliakos@elisabethgruppe.de.
  • Kivitz AJ; Altoona Centre for Clinical Research, Duncansville, PA, USA.
  • Deodhar AA; Oregon Health & Science University, Portland, OR, USA.
  • Braun J; Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Germany.
  • Wei JC; Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Delicha EM; Novartis Pharma AG, Basel, Switzerland.
  • Talloczy Z; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Porter B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Clin Exp Rheumatol ; 36(1): 50-55, 2018.
Article em En | MEDLINE | ID: mdl-28516874
Assuntos
Buscar no Google
Imprimir
XML
PubMed Links

Base de dados: MEDLINE Assunto principal: Espondilite Anquilosante / Interleucina-17 / Anti-Inflamatórios / Anticorpos Monoclonais Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018
Buscar no Google
Imprimir
XML
PubMed Links

Base de dados: MEDLINE Assunto principal: Espondilite Anquilosante / Interleucina-17 / Anti-Inflamatórios / Anticorpos Monoclonais Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018